

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **INSIDE INFORMATION**

#### **PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2024**

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”) is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation has published its 2024 First Quarterly Report for the three months ended 31 March 2024 on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendices of this announcement (the “**Appendices**”) which set out the principal financial information of CSPC Innovation prepared in accordance with the PRC Accounting Standard for Business Enterprises for the three months ended 31 March 2024.

The information in the Appendices is an extract of the unaudited financial statements proposed in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 23 April 2024

*As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*

## APPENDIX I

### PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS

*Unit: RMB Yuan*

	Current reporting period	Corresponding reporting period of last year		Increase/decrease compared with the corresponding reporting period of last year (%)
		Before adjustment	After adjustment	After adjustment
Revenue (Yuan)	524,066,868.93	684,020,305.00	718,720,405.00	-27.08%
Net profit attributable to listed company's shareholders (Yuan)	79,061,260.62	181,976,426.13	129,302,283.05	-38.86%
Net profit attributable to listed company's shareholders less the non-recurring gain/loss (Yuan)	78,171,951.39	179,439,428.78	179,439,428.78	-56.44%
Net cash flows from operating activities (Yuan)	-975,365,408.34	156,910,519.62	296,205,970.86	-429.29%
Basic earnings per share (Yuan/share)	0.0676	0.2939	0.1135	-40.44%
Diluted earnings per share (Yuan/share)	0.0676	0.2939	0.1135	-40.44%
Weighted average return on net assets (%)	1.80%	4.52%	3.09%	-1.29%
	End of current reporting period	End of last year		Increase/decrease compared with the end of last year (%)
		Before adjustment	After adjustment	After adjustment
Total assets (Yuan)	6,467,210,851.42	5,632,123,851.51	7,472,208,452.03	-13.45%
Equity attributable to listed company's shareholders (Yuan)	4,407,734,233.42	5,078,808,635.08	4,364,033,722.20	1.00%

## APPENDIX II

### NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS

*Unit: RMB Yuan*

<b>Items</b>	<b>Amount for current reporting period</b>	<b>Description</b>
Government grants recognised in gain/loss of current period (excluding those closely related to the company's normal operating business, complied with national polices and regulations, granted according to determined standards, and continuously affecting the company's gain/loss)	1,137,807.36	
Non-operating income and expenses other than the above items	628,541.08	
Less: Impact of income tax	504,070.40	
Impact of minority interests (after tax)	372,968.81	
<b>Total</b>	<b>889,309.23</b>	

## APPENDIX III

### DETAILS AND REASONS FOR SIGNIFICANT CHANGES IN MAJOR ACCOUNTING DATA AND FINANCIAL INDICATORS

#### 1. MAJOR ITEMS ON CONSOLIDATED BALANCE SHEET

*Unit: RMB Yuan*

Items	31 March 2024	31 December 2023	Changes	Reasons for changes
Cash and bank balances	2,689,012,812.07	3,770,190,307.96	-28.68%	Mainly due to settlement of outstanding R&D expenses by Megalith, a subsidiary of the company engaged in the biological innovative drug business, for the historical period.
Finance receivables	55,576,068.90	84,562,304.15	-34.28%	Mainly due to increase in the settlement of bills and decrease in bills receivables received by the company during the reporting period as compared with last period.
Trade payables	365,860,707.74	1,264,417,016.17	-71.06%	Mainly due to settlement of outstanding R&D expenses by Megalith, a subsidiary of the company engaged in the biological innovative drug business, for the historical period.

#### 2. MAJOR ITEMS ON CONSOLIDATED INCOME STATEMENT

*Unit: RMB Yuan*

Items	January-March 2024	January-March 2023	Changes	Reasons for changes
Revenue	524,066,868.93	718,720,405.00	- 27.08%	Mainly due to the decrease in the price of caffeine products as compared with the corresponding period of last year, which led to a decrease in the revenue of the principal business during the reporting period, and a revenue of approximately 34 million recognised as a result of the licensing of Nectin-4 ADC products for overseas development and commercialization by Megalith during the corresponding period of last year.
Net profit attributable to owners of the parent	79,061,260.62	129,302,283.05	-38.86%	Mainly due to the decrease in the price of caffeine products, resulting in a decline in the company's profits, and the main pipelines of Megalith were still in the R&D stage and had not yet contributed revenue and profits.
Investment income	-4,612,266.72	-704,630.92	554.56%	Mainly due to the decrease in investment income contributed by the company's associate, Guoxin Huijin.
Credit impairment loss	-5,215,356.78	-342,214.94	1424.00%	Mainly due to the provision for bad debts resulting from the increase in the balance of trade receivables of the company during the reporting period.